|Articles|December 14, 2018

Contagion

  • December 2018
  • Volume 3
  • Issue 6

Controversies in C Difficile Prevention

Author(s)Krista Rossi

Nicola Petrosillo, MD, discusses current controversies in C difficile prevention and treatment.

Prevention is the best practice for any disease; however, which preventive practices are the “best” can vary among health care professionals, making opinions and practices diverse. Such is the case with practices to prevent Clostridium difficile infection.

While at the 6th International C diff Awareness Conference and Health EXPO in Philadelphia, Pennsylvania, Nicola Petrosillo, MD, president, Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie (SIMPIOS) director, Infectious Disease Division, National Institute for Infectious Diseases, “Lazzaro Spallanzani,” in Rome, Italy, discussed current controversies in C difficile prevention and treatment, as well as what factors health care providers should take into account, in an interview with Contagion®’s sister publication, MD Magazine®.

According to Dr. Petrosillo, there are a few points in infection control procedures that are controversial. One of them is how long the patient should be isolated in contact isolation after the end of diarrhea. “The guideline says 48 hours,” Dr. Petrosillo explained. “That’s okay, because after 48 hours, there is no more diarrhea and no more risk for spread of spores in the environment because there is no diarrhea.”

However, the spores can survive up to 4 weeks after the end of diarrhea, and so this practice is risky in some settings where the patients are very sick and have a lot of comorbidities. If they acquire this infection, they can have an increased risk mortality.

“I think that we should consider this measure of 48 hours as very flexible, depending on the setting and patient being treated,” Dr. Petrosillo said. “In some cases, we should [consider] contact isolation for the [entire] stay in the hospital. In some particular cases, it may be needed in order to avoid the spread to other patients.

The second point that is controversial, according to Dr. Petrosillo, is the screening of asymptomatic carriers. “[The] guideline says that asymptomatic carriers should be screened, because otherwise, we do not know what to do with them. What should we treat, what should we not treat? Should we put them in contact isolation? This is constant; this is difficult to manage.”

Results from several studies indicate that for immunocompromised patients, like those who have undergone a bone marrow transplant or elderly people in long-term care facilities, screening of asymptomatic carriers was effective in reducing the rate of C difficile infection in particular conditions, [such as] in outbreak settings and patients with high risk for C difficile infection, he said.

“We should be more flexible and try to understand which patients should be screened: when they are asymptomatic, of course; when they are admitted to the hospital; and which patients and in which settings," Dr. Petrosillo concluded.


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Drawing Borders Around a Borderless Specialty
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.